TEL AVIV, Israel, Aug. 02, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology
company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that
it will host a conference call and live audio webcast on Monday, August 14, 2017 at 8:30am Eastern Time to report second quarter
ended June 30, 2017 financial results.
About VBL
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on
the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s lead oncology product
candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is positioned to
treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every two months. It has been observed
to be well-tolerated in >200 cancer patients and we have observed its efficacy signals in an “all comers” Phase 1 trial as well
as in three tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a Phase 3 pivotal trial for
recurrent Glioblastoma, conducted under an FDA Special Protocol Assessment (SPA).
INVESTOR CONTACT: Michael Rice LifeSci Advisors, LLC (646) 597-6979
